Stable transduction of the neonatal mouse liver using a hybrid rAAV/ sleeping beauty transposon gene delivery system
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3726 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Sharon C Cunningham und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hos…. Hauptthemen laut MEDLINE: Dependovirus, DNA Transposable Elements, Liver, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Tessera Therapeutics, University of Pennsylvania.
Abstract (Originalsprache)
Background
Conventional adeno‐associated viral (AAV) vectors, while highly effective in quiescent cells such as hepatocytes in the adult liver, confer less durable transgene expression in proliferating cells owing to episome loss. Sustained therapeutic success is therefore less likely in liver disorders requiring early intervention. We have previously developed a hybrid, dual virion approach, recombinant AAV (rAAV)/ piggyBac transposon system capable of achieving stable gene transfer in proliferating hepatocytes at levels many fold above conventional AAV vectors. An alternative transposon system, Sleeping Beauty , has been widely used for ex vivo gene delivery; however liver‐targeted delivery using a hybrid rAAV/ Sleeping Beauty approach remains relatively unexplored.
Methods
We investigated the capacity of a Sleeping Beauty (SB)‐based dual rAAV virion approach to achieve stable and efficient gene transfer to the newborn murine liver using transposable therapeutic cassettes encoding coagulation factor IX or ornithine transcarbamylase (OTC).
Results
At equivalent doses, rAAV/SB100X transduced hepatocytes with high efficiency, achieving stable expression into adulthood. Compared with conventional AAV, the proportion of hepatocytes transduced, and factor IX and OTC activity levels, were both markedly increased. The proportion of hepatocytes stably transduced increased 4‐ to 8‐fold from
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospitals Network, Westmead, NSW, Australia.
- Tessera Therapeutics, Inc., Somerville, MA, USA.
- Discipline of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
ORCID-Profile: Sharon C Cunningham
Förderung
- Tessera Therapeutics
- University of Pennsylvania
Zitieren
APA
Cunningham, S. C., Zakas, P. M., Sasaki, N., van Dijk, E. B., Zhu, E., Fu, Y., Salomon, W. E., Citorik, R. J., Rubens, J. R., Cotta-Ramusino, C., Querbes, W., & Alexander, I. E. (2024). Stable transduction of the neonatal mouse liver using a hybrid rAAV/ sleeping beauty transposon gene delivery system. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3726
Vancouver
Cunningham SC, Zakas PM, Sasaki N, van Dijk EB, Zhu E, Fu Y, et al. Stable transduction of the neonatal mouse liver using a hybrid rAAV/ sleeping beauty transposon gene delivery system. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3726
BibTeX
@article{Cunningham2024,
author = {Cunningham, Sharon C and Zakas, Philip M and Sasaki, Natsuki and van Dijk, Eva B and Zhu, Erhua and Fu, Yanfang and Salomon, William E and Citorik, Robert J and Rubens, Jacob R and Cotta-Ramusino, Cecilia and Querbes, William and Alexander, Ian E},
title = {Stable transduction of the neonatal mouse liver using a hybrid rAAV/ sleeping beauty transposon gene delivery system},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3726}
}
EUVIMED